Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025Medicine International

Cardiovascular disease treatment and hyperkalemia: A report of three cases

View Full Paper
Ask AI
Bookmark
Share

Authors

SPSemra PaydaşAHAM Halefoglu

Discussion

Loading...

Member takes

Overview

Case reports on hyperkalemia during RAAS inhibitors therapy, highlighting treatment approaches and outcomes.

Key Points

  • Hyperkalemia was successfully treated within 6 hours in one case using sodium zirconium cyclosilicate.
  • Acute kidney injury regressed in all patients with the correction of hyperkalemia and medication adjustments.
  • RAAS inhibitors, such as ACE inhibitors and ARBs, can lead to hyperkalemia in patients undergoing treatment.
  • Sodium glucose co-transporter 2 inhibitors may prevent hyperkalemia in RAAS therapy patients.

Cite This Study

Paydaş et al. (2025) studied this question.

synapsesocial.com/papers/68c1a78154b1d3bfb60e100bhttps://doi.org/10.3892/mi.2025.253
View Full Paper
Ask AI
Bookmark
Share